

Question the Right People For Bipolar Dx

BY SHERRY BOSCHERT
San Francisco Bureau

SAN FRANCISCO — Diagnosing bipolar disorder requires not just asking the right questions but the right people, Michael J. Gitlin, M.D., said.

More than a third of 600 bipolar disorder patients sought help within a year of becoming symptomatic, but 69% were misdiagnosed (usually as having major depression). In addition, patients saw a mean of four physicians before being correctly diagnosed, a 2003 survey found.

"My quarrel with these data that get published over and over is that the implication is that the physicians" erred, said Dr. Gitlin, professor of clinical psychiatry at the University of California, Los Angeles. "I think it's more complex than that."

Even physicians who ask the right questions often fail to get the whole story from bipolar disorder patients. "You need corroborative evidence" obtained by getting the patient's permission to talk with significant others—a spouse, boyfriend or girlfriend, sibling, or parents, he said.

The same survey of 600 bipolar disorder patients found that they reported manic symptoms far less often than they reported depressive symptoms to physicians when seeking help (*J. Clin. Psychiatry* 2003;64:161-74).

That's not surprising, he noted, because depression feels bad and brings people into treatment. Patients reported manic symptoms other than erratic sleep only 43% of the time or less. Only 37% of patients, for example, told physicians of feeling elated at times.

"That is much more the issue than the idea that we're not probing correctly," he said.

Bipolar disorder patients may not recognize manic or hypomanic symptoms as abnormal, or remember having them. When they're depressed, they're dominated by depressive thoughts and symptoms, and when they're hypomanic they may not remember the depressive symptoms.

Ask significant others as well as the patient about any hypomanic symptoms immediately before or after depressed periods. The highs and lows of bipolar disorder are temporarily related, usually with mania preceding depression, but less commonly in reverse order, Dr. Gitlin said.

Don't just focus on mood, but ask about overactivity, which may be a core feature of hypomania. "The data are not entirely convincing for this, but I think it's something we really ought to be thinking about," he said.

Ask about a family history of mood disorders, and ask whether the patient or family members have ever shown signs of antidepressant-induced hypomania. If you decide to start an antidepressant, educate the patient and significant others to watch for signs of induced hypomania. ■

Subthreshold Bipolar Disorder Is Prevalent

BY MITCHEL L. ZOLER
Philadelphia Bureau

PITTSBURGH — Subthreshold bipolar disorder is highly prevalent and disabling, according to a nationwide survey of more than 9,000 Americans sponsored by the National Institute of Mental Health.

About 2% of the U.S. adult population has subthreshold bipolar disorder, on top of the 2% who have symptoms that meet DSM-IV criteria for bipolar I and II dis-


order, Ronald C. Kessler, Ph.D., said at the Sixth International Conference on Bipolar Disorder. These are "staggeringly large numbers," he said.

The survey results also documented that people who reported having subthreshold bipolar disorder, defined as having episodes with two or more symptoms of bipolar disorder for 4 or more days at a time, had an average of 43 days a year when they were totally unable to work or to perform other normal, daily

activities. This level of impairment was very similar to what was reported by people who met the definition for classic bipolar I or II disorder.

"We need to figure out how we can deliver effective treatment to people" with subthreshold bipolar disorder, said Dr. Kessler, a professor in the department of health care policy at Harvard Medical School in Boston. "The subthreshold people sure have something that's much more impairing than most things we call

INTRODUCING
A **NEW** ONCE-DAILY D-GREE OF RELIEF



POWER UNIMPAIRED

ALL THE POWER OF ALLEGRA® 180 MG
PLUS 24 HOURS OF CONGESTION RELIEF

NEW! 24 Hour
allegra-D®

fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg
Extended-Release Tablets

illness," including asthma, arthritis, and diabetes.

The National Comorbidity Survey–Replication, conducted from February 2001 to April 2003, consisted of face-to-face interviews with 9,282 randomly selected U.S. residents. Each participant was seen by a professional interviewer who followed a script that was designed to collect the data needed to diagnose the presence of any mental illness as well as its impact.

People with symptoms of subthreshold bipolar disorder had clinical characteristics that were very similar to those diagnosed with bipolar I or II disorder. The average age of onset for subthreshold disease was

22.5 years; the average number of lifetime episodes was 9.4; people reported having episodes over a period of an average of 9.2 years, and the 12-month persistence of subthreshold disorder was about 60%.

Severe impairment in at least one life activity was reported by 64% of people who met the criteria for subthreshold bipolar disorder, compared with 70% of those who met criteria for bipolar I and 68% who met criteria for bipolar II. The average reported number of days of impairment per year was 44 for people with bipolar I and 59 for those with bipolar II.

Among those with subthreshold bipolar disorder, 88% also met the diagnostic cri-

teria for another mental illness, compared with 97% of those with bipolar I and 86% of those with bipolar II.

The prevalence of clinically significant, subthreshold bipolar disorder might potentially be even greater, because the definition was arbitrarily set as people who have episodes that last for a minimum of 4 days. It's likely that many more people have episodes that last for 1 day, Dr. Kessler said at the conference, sponsored by the University of Pittsburgh.


Further analysis of data collected in the survey showed that people who met any of the three criteria for bipolar disease reported an average of 50 days a year when

they were unable to work effectively, either because they were absent from work (absenteeism) or because of problems they had at work ("presenteeism").

In contrast, results from the survey showed that people who were diagnosed with major depressive disorder had an average of 32 days a year of absenteeism and presenteeism.

When extrapolated on a national scale, these numbers suggest that all forms of bipolar disorder produce about \$26 billion in lost worker productivity in the United States each year, while major depression leads to about \$44 billion in lost productivity annually, Dr. Kessler said. ■

SMOOTH DELIVERY FOR 24-HOUR RELIEF



Mean plasma pseudoephedrine concentration following single-dose administration of Allegra-D 24 Hour.¹

Due to pseudoephedrine, Allegra-D 24 Hour is contraindicated in patients with narrow-angle glaucoma or urinary retention, in patients receiving monoamine oxidase (MAO) inhibitor therapy or within 14 days of stopping such treatment, and in patients with severe hypertension or severe coronary artery disease

Allegra-D 24 Hour should be used with caution in patients with hypertension, diabetes mellitus, ischemic heart disease, increased intraocular pressure, hyperthyroidism, renal impairment, or prostatic hypertrophy. Care should be taken in the administration of Allegra-D 24 Hour concomitantly with other sympathomimetic amines because combined effects on the cardiovascular system may be harmful to the patient

The most commonly reported adverse events with fexofenadine HCl 180 mg and placebo in seasonal allergic rhinitis patients 12 and older are headache (10.6% vs 7.5%), upper respiratory tract infection (3.2% vs 3.1%), and back pain (2.8% vs 1.4%)

Reference: 1. Data on file, Aventis Pharmaceuticals.

Please see brief summary of prescribing information on the adjacent page.

ALD-JA-19916-1 (035)
© 2005 Aventis Pharmaceuticals Inc.
Aventis Pharmaceuticals,
a member of the sanofi-aventis Group


sanofi aventis
Because health matters

NEW!
24 Hour
allegra-D[®]
fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg
Extended-Release Tablets

POWERUNIMPAIRED